Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1068-1079

  Pavón, Miguel Angel ^a   Parreño, Matilde ^a   León, Xavier ^a   Sancho, Francesc J ^a   Céspedes, Maria Virtudes ^a   Casanova, Isolda ^a   Lopez Pousa, Antonio ^a   Mangues, Maria Antonia ^a   Quer, Miquel ^a   Barnadas, Agustí ^a   Mangues, Ramón ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

DNA PKcs; HNSCC; Induction chemotherapy; Ku70; Ku80; NHEJ; Predictive marker

Indexed keywords

CISPLATIN; DNA; FLUOROURACIL; MESSENGER RNA; ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; DNA BINDING PROTEIN; KU ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; KU70 GENE; KU80 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PREDICTIVE VALIDITY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR RECURRENCE; ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE FREE SURVIVAL; GENETICS; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, NUCLEAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 47249095810     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23635     Document Type: Article

References (71)

1. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24:3693-704.
2. Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001;2:261-9.
3. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004;31:778-85.
4. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G, Al-Sarraf M. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-4.
5. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592-9.
6. Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 2005;27:15-21.
7. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005;55:242-58; quiz 61-2, 64.
8. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8.
9. Whitaker SJ, Powell SN, McMillan TJ. Molecular assays of radiation-induced DNA damage. Eur J Cancer 1991;27:922-8.
10. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, Seno T, Garrett C, Wataya Y. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987;262:8235-41.
11. McHugh PJ, Sones WR, Hartley JA. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 2000;20:3425-33.
12. Haber JE. Partners and pathwaysrepairing a double-strand break. Trends Genet 2000;16:259-64.
13. Korabiowska M, Voltmann J, Honig JF, Bortkiewicz P, Konig F, Cordon-Cardo C, Jenckel F, Ambrosch P, Fischer G. Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity. Anticancer Res 2006;26:2101-5.
14. Gollin SM. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 2001;23:238-53.
15. Shin KH, Kang MK, Kim RH, Kameta A, Baluda MA, Park NH. Abnormal DNA end-joining activity in human head and neck cancer. Int J Mol Med 2006;17:917-24.
16. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 2000;36:916-24.
17. van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001;2:196-206.
18. Ferguson DO, Sekiguchi JM, Chang S, Frank KM, Gao Y, DePinho RA, Alt FW. The nonhomologous end-joining pathway of DNA repair is required for genomic stability and the suppression of translocations. Proc Natl Acad Sci USA 2000;97:6630-3.
19. Peng Y, Zhang Q, Nagasawa H, Okayasu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-4.
20. Tian X, Chen G, Xing H, Weng D, Guo Y, Ma D. The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa. Oncol Rep 2007;18:927-32.
21. Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol (Paris) 2006;54:185-93.
22. Chu G. Double strand break repair. J Biol Chem 1997;272:24097-100.
23. Brown KD, Lataxes TA, Shangary S, Mannino JL, Giardina JF, Chen J, Baskaran R. Ionizing radiation exposure results in up-regulation of Ku70 via a p53/ataxia-telangiectasia-mutated protein-dependent mechanism. J Biol Chem 2000;275:6651-6.
24. Jensen R, Glazer PM. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci USA 2004;101:6134-9.
25. Espinosa E, Vara JA, Redondo A, Sanchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martinez B, Suarez A, Calero F, Baron MG. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 2005;23:7278-85.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
27. Nieuwenhuis EJ, Jaspars LH, Castelijns JA, Bakker B, Wishaupt RG, Denkers F, Leemans CR, Snow GB, Brakenhoff RH. Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates. Clin Cancer Res 2003;9:755-61.
28. Castleman KR. Concepts in imaging and microscopy: color image processing for microscopy. Biol Bull 1998;194:100-7.
29. Maximova OA, Taffs RE, Pomeroy KL, Piccardo P, Asher DM. Computerized morphometric analysis of pathological prion protein deposition in scrapie-infected hamster brain. J Histochem Cytochem 2006;54:97-107.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 2005;115:629-39.
32. Hasina R, Lingen MW. Head and neck cancer: the pursuit of molecular diagnostic markers. Semin Oncol 2004;31:718-25.
33. Panis X, Coninx P, Nguyen TD, Legros M. Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 1990;18:1315-8.
34. Bjork-Eriksson T, West C, Nilsson A, Magnusson B, Svensson M, Karlsson E, Slevin N, Lewensohn R, Mercke C. The immunohistochemical expression of DNA-PKCS and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity. Int J Radiat Oncol Biol Phys 1999;45:1005-10.
35. Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, Hamakawa H. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci 2003;94:894-900.
36. Noguchi T, Shibata T, Fumoto S, Uchida Y, Mueller W, Takeno S. DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol 2002;9:1017-22.
37. Friesland S, Kanter-Lewensohn L, Tell R, Munck-Wikland E, Lewensohn R, Nilsson A. Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy. Head Neck 2003;25:313-21.
38. Lee SW, Cho KJ, Park JH, Kim SY, Nam SY, Lee BJ, Kim SB, Choi SH, Kim JH, Ahn SD, Shin SS, Choi EK, et al. Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:1451-7.
39. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39:2121-35.
40. Wilson CR, Davidson SE, Margison GP, Jackson SP, Hendry JH, West CM. Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer 2000;83:1702-6.
41. Harima Y, Sawada S, Miyazaki Y, Kin K, Ishihara H, Imamura M, Sougawa M, Shikata N, Ohnishi T Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am J Clin Oncol 2003;26:e80-e85.
42. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
43. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-7.
44. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev 1999;13:916-34.
45. Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW. A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 1998;9:367-76.
46. Dip R, Naegeli H. More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit. FASEB J 2005;19:704-15.
47. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, Takeda S. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-508.
48. Wang S, Guo M, Ouyang H, Li X, Cordon-Cardo C, Kurimasa A, Chen DJ, Fuks Z, Ling CC, Li GC. The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc Natl Acad Sci USA 2000;97:1584-8.
49. Woo RA, Jack MT, Xu Y, Burma S, Chen DJ, Lee PW. DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J 2002;21:3000-8.
50. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW, Lee PW. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 2002;99:9825-9.
51. Jack MT, Woo RA, Motoyama N, Takai H, Lee PW. DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J Biol Chem 2004;279:15269-73.
52. Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res 2006;66:10878-84.
53. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000;97:5907-12.
54. Zhao HJ, Hosoi Y, Miyachi H, Ishii K, Yoshida M, Nemoto K, Takai Y, Yamada S, Suzuki N, Ono T. DNA-dependent protein kinase activity correlates with Ku70 expression and radiation sensitivity in esophageal cancer cell lines. Clin Cancer Res 2000;6:1073-8.
55. Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, Sabatier L, Delic J. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 2005;105:4776-83.
56. Gu Y, Jin S, Gao Y, Weaver DT, Alt FW. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci USA 1997;94:8076-81.
57. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
58. Panta GR, Kaur S, Cavin LG, Cortes ML, Mercurio F, Lothstein L, Sweatman TW, Israel M, Arsura M. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004;24:1823-35.
59. Nueda A, Hudson F, Mivechi NF, Dynan WS. DNA-dependent protein kinase protects against heat-induced apoptosis. J Biol Chem 1999;274:14988-96.
60. Tai YT, Podar K, Kraeft SK, Wang F, Young G, Lin B, Gupta D, Chen LB, Anderson KC. Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol 2002;30:212-20.
61. Rooney S, Alt FW, Lombard D, Whitlow S, Eckersdorff M, Fleming J, Fugmann S, Ferguson DO, Schatz DG, Sekiguchi J. Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J Exp Med 2003;197:553-65.
62. Jin S, Inoue S, Weaver DT. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase. Carcinogenesis 1998;19:965-71.
63. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-73.
64. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
65. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
66. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Camicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
67. Eid H, Van der Looij M, Institoris E, Geczi L, Bodrogi I, Olah E, Bak M. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? Anticancer Res 1997;17:2663-9.
68. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58:1793-7.
69. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997;385:123-5.
70. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, Yoo GH, Lee DJ, Forastiere AA, Sidransky D. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
71. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-11.